Literature DB >> 21330455

Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life.

Malena Cohen-Cymberknoh1, David Shoseyov, Eitan Kerem.   

Abstract

The survival of patients with cystic fibrosis (CF) continues to improve. The discovery and cloning of the CFTR gene more than 21 years ago led to the identification of the structure and function of the CFTR chloride channel. New therapies based on the understanding of the function of CFTR are currently under development. The better clinical status and improved survival of patients with CF is not only a result of understanding of the molecular mechanisms of CF but also a result of the development of therapeutic strategies that are based on insights into the natural course of the disease. Current CF treatments that target respiratory infections, inflammation, mucociliary clearance, and nutritional status are associated with improved pulmonary function and reduced exacerbations. Patients benefit from treatment at a specialized CF center by a multidisciplinary dedicated team with emphasis being placed on frequent visits, periodic testing, and monitoring adherence to therapy. The purpose of this review is to survey recent developments in CF care that are responsible for the improved survival and quality of life of patients with CF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21330455     DOI: 10.1164/rccm.201009-1478CI

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  82 in total

1.  Improvements in cystic fibrosis lung disease and airway inflammation associated with etanercept therapy for rheumatoid arthritis: a case report.

Authors:  S Visser; M Martin; D J Serisier
Journal:  Lung       Date:  2012-06-04       Impact factor: 2.584

2.  Neurology of inherited glycosylation disorders.

Authors:  Hudson H Freeze; Erik A Eklund; Bobby G Ng; Marc C Patterson
Journal:  Lancet Neurol       Date:  2012-05       Impact factor: 44.182

3.  Combination of Correctors Rescue ΔF508-CFTR by Reducing Its Association with Hsp40 and Hsp27.

Authors:  Miquéias Lopes-Pacheco; Clément Boinot; Inna Sabirzhanova; Marcelo M Morales; William B Guggino; Liudmila Cebotaru
Journal:  J Biol Chem       Date:  2015-09-02       Impact factor: 5.157

4.  Parent and child perceptions of a self-regulated, home-based exercise program for children with cystic fibrosis.

Authors:  Mary Beth Happ; Leslie A Hoffman; Linda W Higgins; Dana Divirgilio; Dana DiVirgilio; David M Orenstein
Journal:  Nurs Res       Date:  2013 Sep-Oct       Impact factor: 2.381

5.  A Comparison between Two Pathophysiologically Different yet Microbiologically Similar Lung Diseases: Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

Authors:  Daniel E Fenker; Cameron T McDaniel; Warunya Panmanee; Ralph J Panos; Eric J Sorscher; Carleen Sabusap; John P Clancy; Daniel J Hassett
Journal:  Int J Respir Pulm Med       Date:  2018-11-29

6.  A Preclinical Study in Rhesus Macaques for Cystic Fibrosis to Assess Gene Transfer and Transduction by AAV1 and AAV5 with a Dual-Luciferase Reporter System.

Authors:  William B Guggino; Janet Benson; JeanClare Seagrave; Ziying Yan; John Engelhardt; Guangping Gao; Thomas J Conlon; Liudmila Cebotaru
Journal:  Hum Gene Ther Clin Dev       Date:  2017-07-19       Impact factor: 5.032

7.  Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.

Authors:  Michael A Barras; David Serisier; Stefanie Hennig; Katrina Jess; Ross L G Norris
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

8.  Resource Use Evaluation of Tobramycin Formulations in a State Medicaid Program.

Authors:  Shellie L Keast
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

Review 9.  Ion Channel Modulators in Cystic Fibrosis.

Authors:  Martina Gentzsch; Marcus A Mall
Journal:  Chest       Date:  2018-05-08       Impact factor: 9.410

10.  Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?

Authors:  Yanhua Gao; Stefanie Hennig; Michael Barras
Journal:  Clin Pharmacokinet       Date:  2019-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.